Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand…
Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, announced the completion of an up-sized and oversubscribed $175 million Series…
Read More...
Read More...
